This study will evaluate the long-term safety and tolerability of NBI-1065845 as an adjunctive treatment in participants with MDD.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
850
NBI-1065845 tablets
Number of Participants with Treatment-emergent Adverse Events (TEAEs)
Time frame: Baseline through Week 52
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Neurocrine Clinical Site
Huntsville, Alabama, United States
RECRUITINGNeurocrine Clinical Site
Bryant, Arkansas, United States
RECRUITINGNeurocrine Clinical Site
Little Rock, Arkansas, United States
RECRUITINGNeurocrine Clinical Site
Glendale, California, United States
RECRUITINGNeurocrine Clinical Site
Los Angeles, California, United States
RECRUITINGNeurocrine Clinical Site
Oceanside, California, United States
RECRUITINGNeurocrine Clinical Site
Orange, California, United States
RECRUITINGNeurocrine Clinical Site
Pico Rivera, California, United States
RECRUITINGNeurocrine Clinical Site
San Diego, California, United States
RECRUITINGNeurocrine Clinical Site
San Francisco, California, United States
RECRUITING...and 96 more locations